Dr. Lisa Renee Chastant, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 2550 Pass Rd # G, Biloxi, MS 39531 Phone: 228-207-5140 |
Peter William Barnes, MD Dermatology Medicare: Medicare Enrolled Practice Location: 301 Fisher St, Biloxi, MS 39534 Phone: 228-376-3501 |
News Archive
ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.
Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services for seven CHRISTUS Health hospitals throughout Texas and Louisiana.
The researchers assessed the rate at which fat was burned (fat oxidation) during graded leg cycling exercises in thirty 12 year old boys, 17 of whom were obese. The others were lean and healthy.
Memorial Sloan-Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn — which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.
Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.
› Verified 7 days ago